When it comes to the diagnosis of pigmented skin lesions, artificial intelligence is superior to humans. In a study conducted under the supervision of the MedUni Vienna human experts "competed" against computer algorithms. ...
Jun 12, 2019
0
157
Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients ...
Feb 11, 2018
0
140
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by ...
Nov 25, 2021
0
151
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.
Dec 15, 2018
0
58
Disruption to cancer diagnosis services (referrals and routine screening) and people avoiding healthcare because of the COVID-19 pandemic could result in around 3,500 potentially avoidable deaths from the four main cancers ...
Jul 21, 2020
0
29
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.
Jan 12, 2018
0
134
A study co-led by the Universities of Oxford, Birmingham and Southampton and the U.K. Health Security Agency (UKHSA), published in Lancet Oncology today by the U.K. Coronavirus Cancer Evaluation Project, has found that while ...
May 23, 2022
0
61
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology ...
Feb 12, 2018
0
186
Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
Canadian prostate cancer researchers have discovered the genetic fingerprint that explains why up to 30 per cent of men with potentially curable localized prostate cancer develop aggressive disease that spreads following ...
Jan 9, 2017
0
70
